Article | November 13, 2009

The Next Biopharma Business Model

Source: Life Science Leader

By Suzanne Elvidge, Life Science Leader magazine

One of the biggest costs for the biopharma industry is that of drug R&D. “I’ve worked in the biopharma industry for more than 25 years, and I felt that the R&D sector was underperforming,” says Ulrich Grau, Ph.D., president, CEO, and cofounder of Lux Biosciences. “In my days at Hoechst Marion Roussel, one of the predecessor companies of sanofi-aventis, I was responsible for six or seven products in the company’s late-stage pipeline, with an annual budget of around $1B. As each project stays in this phase for about three years, this works out to be about half a billion dollars per project.”

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: